Since then, several HER2-targeting agents, including mAbs, tyrosine kinase inhibitors (TKIs), signal transduction inhibitors, and lately, antibody–drug conjugates (ADCs) have shown preclinical and/or clinical efficacy, spanning all disease stages and treatment settings of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.